Research programme: protein therapeutics - Sanofi
Alternative Names: IL-10 synthorin; IL-15 synthorin; Synthorin™ cytokinesLatest Information Update: 28 Dec 2022
At a glance
- Originator Synthorx
- Developer Sanofi
- Class Analgesics; Anti-infectives; Anti-inflammatories; Antineoplastics; Interleukins; Recombinant proteins
- Mechanism of Action Immunomodulators; Interleukin 15 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Infections; Inflammation; Metabolic disorders; Pain
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Cancer in USA
- 28 Dec 2020 No recent reports of development identified for research development in Infections in USA
- 28 Dec 2020 No recent reports of development identified for research development in Inflammation in USA